Sphera Funds Management’s Crescent Biopharma CBIO Stock Holding History

Sphera Funds Management’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-3,110	Closed	-$3.88M	–	100
2019 Q1	$3.88M	Buy	3,110 +600	+24%	+$687K	0.35%	68
2018 Q4	$2.38M	Hold	2,510	–	–	0.27%	68
2018 Q3	$3.62M	Buy	2,510 +111	+5%	+$168K	0.42%	73
2018 Q2	$3.87M	Buy	2,399 +899	+60%	+$1.55M	0.53%	56
2018 Q1	$2.44M	Sell	1,500 -1,750	-54%	-$3.64M	0.37%	72
2017 Q4	$5.46M	Buy	+3,250	New	+$4.3M	0.64%	34
2017 Q3	–	Sell	-3,208	Closed	-$3.58M	–	139
2017 Q2	$3.58M	Sell	3,208 -4,550	-59%	-$3.76M	0.61%	51
2017 Q1	$4.21M	Buy	7,758 +300	+4%	+$184K	0.82%	30
2016 Q4	$4.55M	Buy	7,458 +277	+4%	+$173K	1.15%	23
2016 Q3	$5.13M	Hold	7,181	–	–	0.84%	27
2016 Q2	$5.22M	Buy	7,181 +3,802	+113%	+$2.62M	1.36%	16
2016 Q1	$2.01M	Buy	+3,379	New	+$1.73M	0.44%	48
2014 Q2	–	Sell	-1,060	Closed	-$1.73M	–	109
2014 Q1	$1.73M	Buy	+1,060	New	+$1.28M	0.4%	55

Other funds holding CBIO

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Sphera Funds Management's CBIO Position: Q2 2019 in Review

Sphera Funds Management sold out of Crescent Biopharma (CBIO) in Q2 2019, closing a stake of 3,110 shares — an estimated $3.88M sold.

Sphera Funds Management first reported a position in CBIO in Q1 2014 and held it in 13 quarters. The position peaked at $5.46M in Q4 2017. 78 funds tracked by Wall St. Rank hold CBIO as of Q2 2019.

Sphera Funds Management reported no remaining Crescent Biopharma position as of Q2 2019 after selling out during the quarter.
Sphera Funds Management sold 3,110 Crescent Biopharma shares in Q2 2019, an estimated $3.88M.
Sphera Funds Management first reported a position in Crescent Biopharma in Q1 2014 and held it in 13 quarters.
Sphera Funds Management's Crescent Biopharma position peaked at $5.46M in Q4 2017.
78 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2019.

Based on Sphera Funds Management's 13F filing for Q2 2019, filed 14 Aug 2019.